Reactor production of no-carrier-added 199Au for biomedical applications
This investigation described development of a technology for the reactor production of no-carrier-added (NCA) 199Au through neutron activation of natural Pt in a research reactor followed by chemical separation of 199Au employing liquid–liquid extraction (LLX) technique using ethyl acetate. A thorough optimization of experimental parameters was carried out primarily to arrive at the separation conditions resulting in quantitative extraction of 199Au into the organic phase. The reported procedure has been found to be prolific in providing 199Au with >95% yields with acceptable radionuclidic and radiochemical purity. An optimized radiochemical processing procedure for obtaining NCA 199Au of requisite purity in high yields suitable for clinical use has been the positive outcome.